IDEXX Laboratories, Inc. $IDXX Shares Purchased by Groupe la Francaise

Groupe la Francaise boosted its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 20.6% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,895 shares of the company’s stock after purchasing an additional 1,349 shares during the period. Groupe la Francaise’s holdings in IDEXX Laboratories were worth $4,216,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in IDXX. Bank of New York Mellon Corp lifted its holdings in IDEXX Laboratories by 156.2% in the second quarter. Bank of New York Mellon Corp now owns 1,451,390 shares of the company’s stock valued at $778,439,000 after acquiring an additional 884,808 shares during the last quarter. Price T Rowe Associates Inc. MD raised its position in IDEXX Laboratories by 71.0% in the first quarter. Price T Rowe Associates Inc. MD now owns 1,988,912 shares of the company’s stock valued at $835,244,000 after purchasing an additional 825,965 shares during the period. Generation Investment Management LLP purchased a new stake in IDEXX Laboratories in the second quarter valued at $304,277,000. Select Equity Group L.P. acquired a new position in shares of IDEXX Laboratories in the 1st quarter valued at $194,834,000. Finally, Nuveen LLC purchased a new position in shares of IDEXX Laboratories during the 1st quarter worth $179,784,000. Hedge funds and other institutional investors own 87.84% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the stock. Piper Sandler reaffirmed a “neutral” rating and issued a $700.00 target price (up previously from $510.00) on shares of IDEXX Laboratories in a research report on Monday, August 11th. Jefferies Financial Group reissued a “buy” rating and issued a $830.00 price target on shares of IDEXX Laboratories in a research note on Tuesday, November 4th. Weiss Ratings raised shares of IDEXX Laboratories from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Monday. BTIG Research boosted their target price on IDEXX Laboratories from $785.00 to $830.00 and gave the company a “buy” rating in a research report on Tuesday, November 4th. Finally, JPMorgan Chase & Co. raised their price target on IDEXX Laboratories from $675.00 to $775.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 4th. Eight investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $730.50.

Insider Activity

In other news, EVP Nimrata Hunt sold 9,425 shares of the firm’s stock in a transaction dated Friday, November 7th. The stock was sold at an average price of $703.34, for a total transaction of $6,628,979.50. Following the sale, the executive vice president owned 21,149 shares of the company’s stock, valued at approximately $14,874,937.66. This trade represents a 30.83% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.98% of the company’s stock.

IDEXX Laboratories Trading Down 0.9%

NASDAQ IDXX opened at $725.93 on Thursday. IDEXX Laboratories, Inc. has a 52 week low of $356.14 and a 52 week high of $769.98. The firm has a 50 day moving average of $672.31 and a two-hundred day moving average of $610.25. The stock has a market capitalization of $57.97 billion, a PE ratio of 57.57, a price-to-earnings-growth ratio of 4.35 and a beta of 1.67. The company has a quick ratio of 0.87, a current ratio of 1.18 and a debt-to-equity ratio of 0.24.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Monday, November 3rd. The company reported $3.22 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.14 by $0.08. The business had revenue of $1.11 billion during the quarter, compared to analysts’ expectations of $1.07 billion. IDEXX Laboratories had a net margin of 24.65% and a return on equity of 67.78%. The company’s revenue for the quarter was up 13.3% on a year-over-year basis. During the same period in the previous year, the company earned $2.80 EPS. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. As a group, research analysts expect that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.